BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 9129866)

  • 1. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.
    de Lalla F
    Drugs; 1997 May; 53(5):789-804. PubMed ID: 9129866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
    J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.
    Dranitsaris G
    Pharmacoeconomics; 1999 Oct; 16(4):343-53. PubMed ID: 10623363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
    Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
    Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of fever in neutropenic patients.
    Bodey GP; Rolston KV
    J Infect Chemother; 2001 Mar; 7(1):1-9. PubMed ID: 11406750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset.
    Lingaratnam S; Thursky KA; Slavin MA; Kirsa SW; Bennett CA; Worth LJ
    Intern Med J; 2011 Jan; 41(1b):121-9. PubMed ID: 21272176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-infective strategies in neutropenia.
    Boogaerts MA
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():167-78. PubMed ID: 8543492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia.
    Bal AM; Gould IM
    Int J Antimicrob Agents; 2007 May; 29(5):501-9. PubMed ID: 17346939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prevention of infections in cancer patients with neutropenia].
    Sinkó J
    Magy Onkol; 2011 Sep; 55(3):155-63. PubMed ID: 21918740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of the febrile neutropenic patient.
    Picazo JJ;
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of the febrile neutropenic patient with cancer.
    Gucalp R
    Oncology (Williston Park); 1991 Jul; 5(7):137-44, 147; discussion 148. PubMed ID: 1837473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis and treatment of bacterial infections: do we need new strategies?
    Micozzi A; Bucaneve G
    Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Meropenem therapy in children with febrile neutropenia].
    Müller J; Kovács G; Garami M; Schmidt M; Fekete G
    Orv Hetil; 2003 Oct; 144(43):2115-20. PubMed ID: 14661443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.
    Taplitz RA; Kennedy EB; Bow EJ; Crews J; Gleason C; Hawley DK; Langston AA; Nastoupil LJ; Rajotte M; Rolston K; Strasfeld L; Flowers CR
    J Clin Oncol; 2018 May; 36(14):1443-1453. PubMed ID: 29461916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.